Definitive Healthcare Stock Earnings Reports

Definitive Healthcare reported Q1 FY26 revenue of $55.9M (down 6% YoY) and adjusted EBITDA of $15.3M (27% margin), with results at or above the high end of guidance. Provider and Diversified end markets (≈60% of revenue) are returning to modest growth; Life Sciences remains pressured due to prior claims-data disruption and a challenging commercialization spending environment. Key operational progress includes improved data quality (fall expansion pack), faster and more numerous integrations (average integration time dropped to ~45 days; nearly 50 new integrations in Q1), stronger customer success activity (highest win-backs in >3 years and several six-figure win-backs), and advancing AI-led product initiatives (first AI-enabled solutions planned later this quarter). Professional services grew ~25% YoY driven by analytics and digital activation; deferred revenue/RPO declined due to a shift toward single-year deals and fewer multi-year commitments. Trailing 12-month unlevered free cash flow was ~ $50M. Management reiterated full-year guidance: revenue $220M–$226M (down 6%–9% YoY) and adjusted EBITDA $55M–$59M (25%–26% margin), while continuing targeted investments (including increased capitalized software development) to drive retention and return to growth. They also recorded a noncash $197M goodwill impairment at quarter end, excluded from adjusted results.